Latest Breaking News On - Carlo rosa - Page 4 : comparemela.com

Italy s DiaSorin sees 60% plunge in COVID-19 revenue next year

Italian diagnostics firm DiaSorin forecast weaker 2022 sales and a near 60% plunge in COVID-19 revenue, with the rapid rollout of vaccines likely to bring the pandemic under control and crimp. | December 18, 2021

Carlo rosaMrinmay deyJan harveyDevika syamnathGiancarlo navachGianluca semeraroIntesa sanpaoloLuminex corpLouise heavensDiasorins pa stock exchangePress releaseNd dia it0003492391

QIAGEN N V : QIAGEN and DiaSorin widen access to latent TB testing in the U S with FDA approval of QuantiFERON-TB Gold Plus assay on LIAISON XS

Additional U.S. approval for LIAISON XS platform builds on FDA approval in 2019 for QuantiFERON assay running on DiaSorin's LIAISON XL analyzer Collaboration now provides full range of automation

Emanuela salviniThierry bernardCarlo rosaJohn gilardiThomas theuringerPhoebe lohExchange commissionDiasorin groupItalian stock exchangeWorld health organizationDrug administrationUs securities exchangeGamma release assayFrankfurt prime standardMolecular diagnosticsApplied testing

Rosa (DiaSorin): Mi auguro che sempre più licei aderiscano al progetto Mad for Science

"Come azienda leader nella ricerca avanzata in campo biomedico, abbiamo deciso di investire nel talento degli insegnanti e delle giovani generazioni, ideando e promuovendo per quattro anni Mad for Science, che ora, alla sua quinta edizione, da progetto di Responsabilità Sociale d’Impresa, è diventato la mission della Fondazione DiaSorin. Mi auguro che, anche grazie all’interlocuzione creatasi con il Ministero dell’Istruzione, sempre più scuole conoscano il progetto e possano coglierne le opportu

Ministero dell istruzioneCarlo rosa

QIAGEN launches the new LIAISON LymeDetect Assay based on QuantiFERON in partnership with DiaSorin

QIAGEN launches the new LIAISON LymeDetect Assay based on QuantiFERON in partnership with DiaSorin
selectscience.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from selectscience.net Daily Mail and Mail on Sunday newspapers.

United statesThierry bernardCarlo rosaLyme borreliosisDiasorin groupProduct newsDetect assayErythema migransWestern europeWestern blotPlus assayChief executive officerValue based careNorth americaஒன்றுபட்டது மாநிலங்களில்தியரி பெர்னார்ட்

DiaSorin S p A : , in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology

Message : Required fields DIASORIN, IN PARTNERSHIP WITH QIAGEN, LAUNCHES THE NEW LIAISON® LYMEDETECT® ASSAY BASED ON QUANTIFERON TECHNOLOGY IN COUNTRIES ACCEPTING CE MARK FOR EARLY DIAGNOSIS OF LYME BORRELIOSIS THE LIAISON® LYMEDETECT® ASSAY IS A SOLUTION FOR THE EARLY DIAGNOSIS OF LYME BORRELIOSIS COMBINING DETECTION OF IGG AND IGM ANTIBODIES AND CELLULAR IMMUNITY THE TEST IS AVAILABLE IN COUNTRIES ACCEPTING THE CE MARK AND IS DESIGNED TO BE RUN ON THE LIAISON® XL AND LIAISON® XS PLATFORMS IN CLINICAL STUDIES, THE ASSAY SHOWED, WITHIN 21 DAYS FROM THE FIRST EVIDENCE OF INFECTION, A SENSITIVITY OF 74% VERSUS THAT OF EXISTING ESTABLISHED METHODS AT 49%, WHILE ALSO DEMONSTRATING A HIGH DIAGNOSTIC SPECIFICITY OF 100%

Emanuela salviniThierry bernardCarlo rosaJohn gilardiRobert reitzeThomas theuringerPhoebe makielloLyme borreliosisPhoebe lohRoberta sykesExchange commissionDiasorin groupLife sciencesItalian stock exchangeUs securities exchangeFrankfurt prime standard